JPMorgan raised the firm’s price target on HCA Healthcare to $257 from $235 and keeps an Overweight rating on the shares. The firm believes the managed care group remains fundamentally well positioned coming out of Q4 but adjusted multiples and ratings across the sector to reflect valuations more in-line with historical levels. In addition, the near-term Medicare Advantage rate outlook is disappointing with the Centers for Medicare and Medicaid Services announcing a 2% preliminary rate cut next year versus the market’s expectation for an increase in the range of 0%-2%, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCA:
- HCA Healthcare price target raised to $285 from $260 at Argus
- HCA Healthcare exec Berres sells 4,000 common shares
- HCA Healthcare price target raised to $300 from $230 at Raymond James
- HCA Healthcare price target raised to $285 from $240 at Loop Capital
- HCA Healthcare price target raised to $283 from $239 at RBC Capital